Transcriptional Changes in Chronic Rhinosinusitis with Asthma Favor a Type 2 Molecular Endotype Independent of Polyp Status.
asthma
chronic rhinosinusitis
endotype
gene transcription
inflammatory markers
nasal polyposis
Journal
Journal of asthma and allergy
ISSN: 1178-6965
Titre abrégé: J Asthma Allergy
Pays: New Zealand
ID NLM: 101543450
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
02
2021
accepted:
16
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Data regarding the inflammatory profile of patients with asthma and chronic rhinosinusitis (CRS-A) with (CRSwNP-A) and without (CRSsNP-A) nasal polyposis remain limited. Define and compare systemic transcriptional changes in patients with CRS-A to those with non-asthma-related CRS with (CRSwNP) and without nasal polyposis (CRSsNP). Thirty-four patients with CRS-A (n=19) and CRS (n=15) were prospectively enrolled into an observational study. Demographic information and subjective and objective disease severity measures were recorded. Multiplex gene expression analysis of mRNA extracted from peripheral blood was performed. A total of 594 genes associated with innate/adaptive immunity were analyzed using NanoString technology. Gene expression ratios were reported for genes that were differentially expressed among these cohorts. Linear regression analysis was used to compare the mRNA transcript copy numbers for each gene with disease severity. There was no significant difference in age, gender, nasal polyposis, or health-related quality of life measures between the two groups (p>0.05). HLA class II histocompatibility antigen, DRB3-1 beta chain ( Patients with CRSsNP-A demonstrate a molecular endotype associated with a Th2-dominant inflammatory profile compared to CRSsNP. Patients with CRSwNP-A similarly demonstrate an overrepresentation of genes associated with Th2-driven inflammation compared to patients with CRSwNP.
Sections du résumé
BACKGROUND
BACKGROUND
Data regarding the inflammatory profile of patients with asthma and chronic rhinosinusitis (CRS-A) with (CRSwNP-A) and without (CRSsNP-A) nasal polyposis remain limited.
OBJECTIVE
OBJECTIVE
Define and compare systemic transcriptional changes in patients with CRS-A to those with non-asthma-related CRS with (CRSwNP) and without nasal polyposis (CRSsNP).
METHODS
METHODS
Thirty-four patients with CRS-A (n=19) and CRS (n=15) were prospectively enrolled into an observational study. Demographic information and subjective and objective disease severity measures were recorded. Multiplex gene expression analysis of mRNA extracted from peripheral blood was performed. A total of 594 genes associated with innate/adaptive immunity were analyzed using NanoString technology. Gene expression ratios were reported for genes that were differentially expressed among these cohorts. Linear regression analysis was used to compare the mRNA transcript copy numbers for each gene with disease severity.
RESULTS
RESULTS
There was no significant difference in age, gender, nasal polyposis, or health-related quality of life measures between the two groups (p>0.05). HLA class II histocompatibility antigen, DRB3-1 beta chain (
CONCLUSION
CONCLUSIONS
Patients with CRSsNP-A demonstrate a molecular endotype associated with a Th2-dominant inflammatory profile compared to CRSsNP. Patients with CRSwNP-A similarly demonstrate an overrepresentation of genes associated with Th2-driven inflammation compared to patients with CRSwNP.
Identifiants
pubmed: 33911879
doi: 10.2147/JAA.S301825
pii: 301825
pmc: PMC8071779
doi:
Types de publication
Journal Article
Langues
eng
Pagination
405-413Subventions
Organisme : NIAID NIH HHS
ID : R44 AI126987
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021 Gill et al.
Déclaration de conflit d'intérêts
Abigail Pulsipher: Financial interests in GlycoMira Therapeutics. Jeremiah A Alt: Financial interest and/or other relationships with GlycoMira Therapeutics, Inc. (Salt Lake City, UT; USA) is a consultant for Medtronic ENT and OptiNose, which are not affiliated with this research.
Références
Int Forum Allergy Rhinol. 2019 Apr;9(4):402-408
pubmed: 30570840
Am J Rhinol Allergy. 2016 Mar-Apr;30(2):128-33
pubmed: 26980393
Int Forum Allergy Rhinol. 2012 Nov;2(6):437-43
pubmed: 22696495
Am J Rhinol Allergy. 2012 Jan-Feb;26(1):12-7
pubmed: 22391069
PLoS One. 2010 Jul 06;5(7):e11450
pubmed: 20625511
Otolaryngol Head Neck Surg. 1997 Sep;117(3 Pt 2):S35-40
pubmed: 9334786
Curr Med Res Opin. 2020 Jun;36(6):1043-1048
pubmed: 32270714
PLoS One. 2017 Dec 18;12(12):e0185244
pubmed: 29253858
J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1061-1070.e3
pubmed: 28286156
Immunol Rev. 2011 Jul;242(1):10-30
pubmed: 21682736
Medicina (Kaunas). 2019 Apr 05;55(4):
pubmed: 30959833
J Biol Chem. 2010 Mar 12;285(11):8256-67
pubmed: 20051514
Rhinology. 1993 Dec;31(4):183-4
pubmed: 8140385
Natl Vital Stat Rep. 2013 May 8;61(4):1-117
pubmed: 24979972
Am Fam Physician. 2018 Oct 15;98(8):508-515
pubmed: 30277728
Mol Med Rep. 2018 Jan;17(1):1219-1227
pubmed: 29115522
Nat Immunol. 2012 Jan 08;13(2):152-61
pubmed: 22231518
Eur Respir J. 2018 May 17;51(5):
pubmed: 29650561
Allergy Asthma Immunol Res. 2011 Oct;3(4):265-72
pubmed: 21966607
Am J Respir Crit Care Med. 2017 Jun 1;195(11):1409-1411
pubmed: 28569573
Arch Otolaryngol Head Neck Surg. 1997 Nov;123(11):1175-9
pubmed: 9366696
J Allergy Clin Immunol. 2016 Jun;137(6):1898-1902.e7
pubmed: 26993036
J Allergy Clin Immunol. 2013 Apr;131(4):977-93, 993.e1-5
pubmed: 23540616
Int Forum Allergy Rhinol. 2016 Feb;6 Suppl 1:S22-209
pubmed: 26889651
Clin Otolaryngol. 2009 Oct;34(5):447-54
pubmed: 19793277
Expert Rev Respir Med. 2020 Dec;14(12):1197-1205
pubmed: 32875924
Otolaryngol Head Neck Surg. 2015 Apr;152(2 Suppl):S1-S39
pubmed: 25832968
Mol Med Rep. 2019 May;19(5):3855-3863
pubmed: 30864741
Proc Am Thorac Soc. 2009 May 1;6(3):249-55
pubmed: 19387025
NPJ Prim Care Respir Med. 2019 Oct 21;29(1):37
pubmed: 31636268
Clin Exp Med. 2020 Feb;20(1):87-95
pubmed: 31853669
Clin Transl Allergy. 2020 Jul 3;10:26
pubmed: 32637070
J Immunol. 2016 Jul 15;197(2):655-64
pubmed: 27271570
Br J Pharmacol. 2005 May;145(1):114-22
pubmed: 15723090